Compare · ORKA vs TNFA
ORKA vs TNFA
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and TNF Pharmaceuticals Inc. (TNFA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and TNFA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA carries a market cap of $3.45B.
- Over the past year, ORKA is up 389.1% and TNFA is down 68.3% - ORKA leads by 457.4 points.
- ORKA has hit the wire 14 times in the past 4 weeks while TNFA has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 0 for TNFA).
PerformanceORKA+77.48%TNFA-68.28%
2026-02-11+0.00%2026-06-03
- Company
- Oruka Therapeutics Inc.
- TNF Pharmaceuticals Inc.
- Price
- $57.23+3.57%
- $5.17+47.50%
- Market cap
- $3.45B
- -
- 1M return
- -13.90%
- -24.75%
- 1Y return
- +389.15%
- -68.28%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 14
- 0
- Recent ratings
- 11
- 0
Latest ORKA
- SEC Form 4 filed by Director Dambkowski Carl
- SEC Form 4 filed by Director Kulkarni Samarth
- SEC Form 4 filed by Director Martin Christopher Nathan
- SEC Form 4 filed by Director Ball Kristine M
- SEC Form 4 filed by Director Fairmount Funds Management Llc
- Oruka Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation
- Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
- Director Dambkowski Carl exercised 62,260 shares at a strike of $7.95 and sold $6,191,366 worth of shares (105,000 units at $58.97) as part of a pre-agreed trading plan, decreasing direct ownership by 37% to 73,743 units (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 7,833 shares at a strike of $28.80 and sold $607,806 worth of shares (10,290 units at $59.07) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 16,406 units (SEC Form 4)
Latest TNFA
- TNF Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS"
- TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol "QCLS" to Reflect Strategic Focus on Quantum Class Photonic Computing
- TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
- TNF Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Amendment: TNF Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form D filed by TNF Pharmaceuticals Inc.
- TNF Pharmaceuticals Announces Closing of $7 Million Private Placement
- TNF Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits